Patents matching “adoptive”

US 12419870

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

US 12415843

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

The Regents of the University of California · Granted Sep 16, 2025 · Expires Sep 11, 2045

US 12397028

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

US 12295971

Compositions and methods for enhancing adoptive T cell therapeutics

The Regents of the University of California · Granted May 13, 2025 · Expires May 8, 2045

US 12281329

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12121540

CBL inhibitors and compositions for use in adoptive cell therapy

NURIX THERAPEUTICS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

US 12036256

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. · Granted Jul 16, 2024 · Expires Jul 11, 2044

US 12036241

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Jul 16, 2024 · Expires Jul 11, 2044

US 11932870

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

US 11925663

Methods of managing tumor flare in adoptive immunotherapy

Atara Biotherapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

US 11433131

Adoptive cell therapy using spherical nucleic acids (SNAs)

Northwestern University · Granted Sep 6, 2022 · Expires Sep 1, 2042

US 11413309

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Aug 16, 2022 · Expires Aug 11, 2042

US 11401506

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

Board nf Regents The Inivercitvof Texas Cvctom · Granted Aug 2, 2022 · Expires Jul 28, 2042

US 11318164

Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy

Nektar Therapeutics · Granted May 3, 2022 · Expires Apr 28, 2042

US 11096964

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Aug 24, 2021 · Expires Aug 19, 2041

US 9675633

miRNA for treating cancer and for use with adoptive immunotherapies

The Board of Regents of the University of Texas System · Granted Jun 13, 2017 · Expires Jun 8, 2037

US 9512401

B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

The Board of Regents of the University of Texas System · Granted Dec 6, 2016 · Expires Dec 1, 2036

US 9074185

Adoptive cell therapy with young T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 7, 2015 · Expires Jul 2, 2035

US 8883500

Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy

Northwestern University · Granted Nov 11, 2014 · Expires Nov 6, 2034

US 8541185

Method of predicting responsiveness to autologous adoptive cell transfer therapy

TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Sep 24, 2013 · Expires Sep 19, 2033

US 8383099

Adoptive cell therapy with young T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 26, 2013 · Expires Feb 21, 2033

US 7998736

Adoptive immunotherapy with enhanced T lymphocyte survival

The United States of America, as represented by the Department of Health and Human Services · Granted Aug 16, 2011 · Expires Aug 11, 2031